Who is sponsoring NCT04277663?

NCT04277663 is sponsored by Innovent Biologics (Suzhou) Co. Ltd..

What drugs are being tested in NCT04277663?

Interventions in NCT04277663: IBI310+IBI308, IBI308, High-dose recombinant interferon a-2B.

What condition does NCT04277663 study?

NCT04277663 studies Acral Melanoma That Has Been Removed by Surgery.

Is NCT04277663 still recruiting?

NCT04277663 is currently terminated. Last updated 9 March 2023.

Last reviewed 2023-03-09 · How we verify

NCT04277663

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

Terminated Phase 3 Last updated 9 March 2023

What this trial tests

Phase 3 trial testing IBI310+IBI308 in Acral Melanoma That Has Been Removed by Surgery in 136 participants. Terminated before completion.

Timeline

17 April 2020

Primary endpoint
28 February 2023

28 February 2023

Quick facts

Lead sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	136
Start date	17 April 2020
Primary completion	28 February 2023
Estimated completion	28 February 2023
Sites	1 location across China

Drugs / interventions tested

IBI310+IBI308 — full drug profile →
IBI308 — full drug profile →
High-dose recombinant interferon a-2B — full drug profile →

Conditions studied

Acral Melanoma That Has Been Removed by Surgery — all drugs for Acral Melanoma That Has Been Removed by Surgery →

Sponsor

Innovent Biologics (Suzhou) Co. Ltd. — full company profile →

Who can join

18 and older, any sex, with Acral Melanoma That Has Been Removed by Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase III randomized, control, multi-center study of recombinant humanized anti-PD-1 mAb in combination with CTLA4 mAb for injection compared to high-Dose interferon in patients with acral melanoma that has been removed by surgery.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Antibodies to watch in 2021.
Kaplon H, Reichert JM. · · 2021 · cited 215× · PMID 33459118 · DOI 10.1080/19420862.2020.1860476
Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
Mao L, Qi Z, Zhang L, Guo J, et al · · 2021 · cited 119× · PMID 34149718 · DOI 10.3389/fimmu.2021.680407
Acral melanoma: new insights into the immune and genomic landscape.
Carvalho LAD, Aguiar FC, Smalley KSM, Possik PA. · · 2023 · cited 21× · PMID 37913653 · DOI 10.1016/j.neo.2023.100947
Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review.
Zheng Q, Li J, Zhang H, Wang Y, et al · · 2020 · cited 21× · PMID 33344255 · DOI 10.3389/fonc.2020.602705

Verify or expand the search:

Other Innovent Biologics (Suzhou) Co. Ltd. trials

Trials by the same sponsor.

NCT07502534 — A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers · Phase 1 · not yet recruiting
NCT07469800 — Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity · Phase 3 · not yet recruiting
NCT07473960 — IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia · Phase 3 · recruiting
NCT07483567 — IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastri · Phase 2 · not yet recruiting
NCT07483554 — IBI343 in Combination Therapy for Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04277663 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Innovent Biologics (Suzhou) Co. Ltd.
Last refreshed: 9 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04277663.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing